STOCK TITAN

Travere Therapeutics Inc - TVTX STOCK NEWS

Welcome to our dedicated news page for Travere Therapeutics (Ticker: TVTX), a resource for investors and traders seeking the latest updates and insights on Travere Therapeutics.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Travere Therapeutics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Travere Therapeutics's position in the market.

Rhea-AI Summary
Travere Therapeutics grants inducement equity grants to new employees
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.5%
Tags
none
-
Rhea-AI Summary
Travere Therapeutics completes sale of bile acid product portfolio to Mirum Pharmaceuticals for $210 million upfront payment and potential milestone payments of up to $235 million. Mirum acquires rights to Cholbam® and Chenodal®, expanding its leadership in rare liver disease and Phase 3 label expansion opportunity.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.57%
Tags
none
-
Rhea-AI Summary
Mirum acquires Travere's rights and assets for Cholbam® and Chenodal®, paying $210 million upfront with potential for $235 million in milestone payments. Expands Mirum's rare liver disease portfolio and strengthens Travere's financial foundation.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.46%
Tags
acquisition
Rhea-AI Summary
Mirum acquires Travere's rights and assets for Cholbam® and Chenodal®, paying $210 million upfront with potential for $235 million in milestone payments. Expands Mirum's rare liver disease portfolio and strengthens Travere's financial foundation.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.57%
Tags
acquisition
-
Rhea-AI Summary
Travere Therapeutics to present at Wells Fargo Healthcare Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.13%
Tags
conferences
-
Rhea-AI Summary
Travere Therapeutics will present clinical data from the Phase 1/2 COMPOSE Study of pegtibatinase at the SSIEM Annual Symposium. The data highlights the urgent need for new treatments for classical homocystinuria (HCU).
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.04%
Tags
conferences
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.63%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.67%
Tags
earnings
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.07%
Tags
conferences earnings
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.66%
Tags
none
Travere Therapeutics Inc

Nasdaq:TVTX

TVTX Rankings

TVTX Stock Data

586.72M
60.45M
1.01%
115.18%
13.24%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States
San Diego